A cluster randomized trial to assess the efficacy of the Diabetes Medication Choice decision aid among Greek patients with type 2 diabetes mellitus compared with usual care. The tool will serve as a facilitator for the Shared Decision Making process.

Inclusion Criteria:

• Type 2 diabetes mellitus for more than one year
• Agree to be followed for at least 6 months
• Willing to respond to survey questions immediately following the visit
• HbA1c value between 7.5% and 10%
• Need treatment intensification and there are more than one available treatment options

Exclusion Criteria:

• Decide not to intensify treatment or to intensify treatment through lifestyle modification, which is a sine qua non for diabetes treatment
• Is to transfer to another practice within the next 6 months
• Significant cognitive (e.g. dementia) or sensory limitations (e.g. blind) or other reasons (e.g. fatigue, limited attention, sleep deprivation) for which, in the judgment of the study personnel, they could not reasonably provide written informed consent or be able to use the decision aid
• Planning to enter a long-term care facility (e.g. nursing home) where medications will be administered by clinical personnel after hospital discharge
• Enrolled in other studies that require prolonged participation and follow-up
• Unable to speak Greek at a level necessary to complete the patient surveys and ensure involvement in decision making
• Women known to be pregnant